401 related articles for article (PubMed ID: 16134130)
1. A review of methods for futility stopping based on conditional power.
Lachin JM
Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
[TBL] [Abstract][Full Text] [Related]
2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
3. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
4. A composite design for transition from a preliminary to a full-scale study.
Lachin JM; Younes N
Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
[TBL] [Abstract][Full Text] [Related]
5. Over-ruling a group sequential boundary--a stopping rule versus a guideline.
Lan KK; Lachin JM; Bautista O
Stat Med; 2003 Nov; 22(21):3347-55. PubMed ID: 14566919
[TBL] [Abstract][Full Text] [Related]
6. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
7. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
8. Early stopping to accept H(o) based on conditional power: approximations and comparisons.
Betensky RA
Biometrics; 1997 Sep; 53(3):794-806. PubMed ID: 9290216
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
Tan M; Xiong X; Kutner MH
Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
[TBL] [Abstract][Full Text] [Related]
10. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
11. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
12. Implementation of group sequential logrank tests in a maximum duration trial.
Lan KK; Lachin JM
Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
[TBL] [Abstract][Full Text] [Related]
13. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
Kim K; Boucher H; Tsiatis AA
Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
[TBL] [Abstract][Full Text] [Related]
14. Multiple imputation for early stopping of a complex clinical trial.
Betensky RA
Biometrics; 1998 Mar; 54(1):229-42. PubMed ID: 9544518
[TBL] [Abstract][Full Text] [Related]
15. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
Cheng Y; Shen Y
Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
[TBL] [Abstract][Full Text] [Related]
16. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
17. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
Tan M; Xiong X
Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
[TBL] [Abstract][Full Text] [Related]
18. Self-designing trial combined with classical group sequential monitoring.
Yin G; Shen Y
J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of experiments with adaptive interim analyses.
Bauer P; Köhne K
Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
[TBL] [Abstract][Full Text] [Related]
20. A general statistical principle for changing a design any time during the course of a trial.
Müller HH; Schäfer H
Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
